TRIALS

GALE: evaluation of the long-term safety and efficacy of pegcetacoplan in patients with GA secondary to AMD

STATUS:

Pausat

DESCRIPTION

This is a Phase III, open-label, multicenter clinical trial evaluating the long-term safety and efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Objectives

The primary objective of this study is to evaluate the long-term safety of intravitreal pegcetacoplan, as well as lesion changes measured by autofluorescence.

Drug

FARMAC:

Biochemical, genetic, and clinical evidence in humans indicates that the complement system plays a role in the etiology of AMD.

Complement protein C3 (which has a pro-inflammatory action), the membrane attack complex, and complement factor H are present in drusen and basal laminar deposits in patients with AMD.

Pegcetacoplan is an intravitreal drug that blocks the action of C3. Its main effect is anti-inflammatory.

Population

This study only includes patients who have participated in the APL2-103 study or have completed month 24 of treatment in the APL2-303 (DERBY) or APL2-304 (OAKS) studies.

Duration

La durada de l’assaig és de 3 anys.

Associated Pathologies

No results found.

If you found this interesting, feel free to share it here:

Última modificació: 01/09/2025
Scroll to Top

SCHEDULE

WE CALL YOU

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.